CD39 shields lungs from P2RX7-driven damage in tuberculosis

Tuberculosis produces a range of lung lesions, and in its severe forms the disease can cause necrotic pneumonia that makes illness worse and helps the infection spread. Researchers led by Gislane de Almeida Santos set out to understand why some tuberculosis infections progress to these destructive, necrotic forms. Previous work had implicated ATP-gated P2RX7 ion channels as a driver of immune cell death and severe disease, but how P2RX7 activity is kept in check inside the lung has been unclear. Working in models of severe experimental tuberculosis, the team focused on CD39, a cell-surface enzyme known to break down extracellular ATP. The study asked whether CD39 could control the harmful P2RX7 pathway and thereby protect lung tissue. What they found changes how we think about the molecular checks and balances that determine whether an infected lung heals or develops expanding necrotic damage. Rather than being a passive bystander, CD39 emerged as an active regulator that helps limit the cascade of events leading from infection to tissue breakdown, bacterial spread, and excessive inflammation.

The core discovery reported by Gislane de Almeida Santos and colleagues is that CD39 acts through its enzymatic activity on the cell surface to prevent a sequence of events that otherwise leads to necrotic lesions. In tuberculosis, necrotic granuloma-like structures release extracellular ATP (eATP), and that eATP can engage P2RX7 ion channels on immune cells to trigger cell death. The team showed that CD39 degrades eATP before it can activate P2RX7, and this degradation preserves the survival of infected macrophages. By protecting macrophages from P2RX7-mediated necrotic death, CD39 reduced lung tissue damage, limited bacterial dissemination beyond the initial site of infection, and restrained excessive inflammatory responses. Mechanistically, the results place CD39 upstream of P2RX7 in a simple but powerful pathway: granuloma-like release of eATP → potential P2RX7 activation and immune cell death → CD39-mediated eATP degradation prevents P2RX7 activation → macrophage survival and containment of damage. These findings were made in the context of severe experimental tuberculosis models and focus specifically on the interplay of CD39, eATP, and P2RX7.

The implications of this work are clear from the molecular chain the authors describe: CD39 is not just another molecule present in infected tissue, it is an essential component of the regulatory machinery that determines whether tuberculosis remains localized or escalates into necrotic, transmissible disease. By degrading eATP and preventing P2RX7 activation, CD39 helps maintain macrophage viability, which in turn limits inflammation, tissue destruction, and bacterial spread. That framing suggests a route for future research aimed at preserving lung structure and function during tuberculosis by bolstering CD39 activity or otherwise interrupting the eATP–P2RX7 axis. While the study focuses on experimental models and does not itself test therapies, it uncovers a clear molecular target and a plausible mechanism to explain how necrotic lesions form. For clinicians and scientists, the take-home is that controlling extracellular ATP signaling via CD39 could be an important strategy to reduce the severe, necrotic forms of tuberculosis that drive poor outcomes and transmission.